Cell No. : Cell Name
RCB2120 : TSt-4/N-DLL1 update : 2023/10/16 |
||||
Comment | Original murine mesenchymal cell line was derived from fetal thymus tissue. By retrovirally introducing DLL1 gene, this cell line can support the generation of T cells (up to DP stage) from muirne hematopietic stem/progenitors. Human NGF receptor is also introduced, and is expressed as a marker on cell surface. | |||
Comment from the depositor | ||||
Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. | |||
Remarks | ||||
Order Form | Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)   | |||
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp). | ||||
Basic information | Depositor | Kawamoto, Hiroshi | ||
Originator | Kawamoto, Hiroshi | |||
Year of deposit | 2005 | |||
Animal | _mouse < Mammals | |||
Age at sampling | fetus | |||
Tissue | thymus | |||
Classification | transformed | |||
Recombinant | recombinant | |||
Exogene | MSCV-IRES-NGFR(human),murine DLL1 (delta-like 1) | Lifespan | infinite | |
Morphology | fibroblast-like | |||
Cellosaurus(Expasy) | CVCL_B977 | |||
Medium | Medium List | Culture type | Adherent cells | |
Culture medium | RPMI1640 + 5% FBS | |||
Antibiotics | Free | Passage method | 0.25% Trypsin | Culture information | Passage ratio | 1 : 4 split |
SC frequency | Subculture : 2 times/week | |||
Temperature | 37 ℃ | |||
CO2 concentration | 5 % | |||
Freeze medium | Medium + 10% DMSO | |||
Freezing method | Slow freezing | |||
SSLP(mouse) | OK | |||
Isozyme | LD, NP | |||
Images | ||||
|
|
|||
Reference information | Reference | 1 | ||
User's Publication | 1 | |||